Highlights PainReform Ltd.

Equities

PRFX

IL0011651580

Market Closed - Nasdaq Other stock markets 21:30:00 31/05/2024 BST			5-day change	1st Jan Change
0.71 ^USD	-.--%		+1.43%	-74.18%

05-15	PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	04-16	MT
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	04-09	CI
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	04-02	CI
PainReform Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief	01-03	CI
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-15	CI
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File	11/09/23	CI
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary	07/09/23	CI
PainReform Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	10/08/23	CI
PainReform Regains Compliance With Nasdaq Listing Rule	19/07/23	MT
PainReform's Second Part of Phase 3 Trial of PRF-110 Faces Potential Delay	07/06/23	MT
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	07/06/23	CI
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	18/05/23	CI
PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
PainReform Ltd. Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	01/05/23	CI
PainReform Ltd. Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery	28/03/23	CI
PainReform Ltd. Commences Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery	14/03/23	CI
PainReform : CONDENSED FINANCIAL STATEMENTS - Form 6-K	15/11/22	PU
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	14/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PainReform Ltd.

Equities

PRFX

IL0011651580

Highlights

Filters